PALM BEACH, Florida, May 9, 2019 /PRNewswire/ -- As the baby boomer generation ages, there is an increased need no a demand by these aging patients to avert vision and blindness problems that come with aging. An industry report GBI Research stated that the Ophthalmology global markets are projected to grow to $26 billion in 2022. That same report said: "Ophthalmology is a therapy area that deals with the diagnosis, treatment and prevention of diseases associated with the eyes and visual system. Most eye disorders occur over a long period of time, and are initially asymptomatic or cause only a slight decrease in vision. However, over time this becomes quite marked." Another industry source added: "Innovations and exciting developments have boomed in ophthalmology over the last few decades. As a result of all the hard work, progression of diseases such as age-related macular degeneration and diabetic macular edema that lead to poor vision and even blindness, can now be halted. Active Healthcare companies in the markets this week include: Guardion Health Sciences, Inc. (NASDAQ: GHSI), BioSig Technologies, Inc. (NASDAQ: BSGM), ViewRay, Inc. (NASDAQ: VRAY), Rockwell Medical, Inc. (NASDAQ: RMTI), PTC Therapeutics, Inc. (NASDAQ: PTCT).

The article continued with "Many academic institutes and biotech companies initiated the research and development of gene and other advanced medical therapies for severe ocular diseases leading to severe visual disability or blindness. Currently, many gene therapy products are being developed preclinically and evaluated in trials for hereditary or genetically linked severe ocular diseases like retinal dystrophies, achromatopsia, retinoschisis, choroideremia, and age-related macular degeneration. But also, other innovative approaches, not on DNA but on RNA level, like RNA editing with antisense oligonucleotides, are under development for Leber's congenital amaurosis and Usher syndrome."

Guardion Health Sciences, Inc. (NASDAQ: GHSI) BREAKING NEWS:  Guardion Health Sciences, an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, today announced the results of a study from research scientists at the Western University  College of Optometry to clinically evaluate the visual benefits of the Company's micronized liquid formula Lumega-Z as compared to the AREDS 2 softgel supplement in individuals with retinal drusen and at risk of developing Age-Related Macular Degeneration (AMD).

Dr. David Evans, Ph.D., Guardion's Chief Science Officer, commenting on the results of the study, stated, "We are pleased to present for the first-time clinical data showing the beneficial effects of our liquid lipid-based formula Lumega-Z as compared to the AREDS 2 softgel supplement. This data supports numerous clinical reports that we have showing substantial clinical improvements in patients who switched from the AREDS 2 softgel to Lumega-Z. This data also extends the important work conducted by the National Eye Institute emphasizing the importance of nutritional therapy in combating the growing epidemic of vision loss from Age-Related Macular Degeneration." Read this and more news for Guardion Health at: https://www.financialnewsmedia.com/news-ghsi/


Other recent developments in the healthcare, biotech industries:

BioSig Technologies, Inc. (NASDAQ: BSGM) a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, recently announced that the Company conducted patient cases using the PURE EP(tm) System at Indiana University School of Medicine. The cases were conducted under the leadership of Prof. John M. Miller, M.D. and Dr. Mithilesh K. Das, MBBS.

"We found that the clarity of the signals made a great difference in the confidence with which we could continue applying ablation energy to an abnormal pathway that was in the region of the normal conduction system; BioSig technology allowed us to see a clear signal from the normal conduction pathway during ablation that was obscured by noise on our standard recordings. It was a jaw-dropper!" commented Prof. M. Miller, M.D.

ViewRay, Inc. (NASDAQ: VRAY) recently announced that the company's MRIdian MRI-guided radiation therapy system will be featured at the Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO), with a number of presentations and posters highlighting MRIdian research and clinical experience. The ESTRO meeting will be held April 26-30 in Milan, Italy.

MRIdian MRI-guided radiation therapy offers continuous, high-quality soft tissue visualization and automated beam-gating to improve the accuracy and precision of cancer treatment. The significant interest around MRIdian is reflected in more than 25 MRIdian presentations and posters accepted as part of ESTRO's Scientific Sessions. These abstracts were submitted by MRIdian users from around the world.

Rockwell Medical, Inc. (NASDAQ: RMTI)  a global biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal disease (ESRD) and chronic kidney disease (CKD), recently announced the commencement of commercial sales of Dialysate Triferic^® in the United States.

Triferic is a novel therapeutic platform for the treatment of anemia that replaces ongoing iron losses by a process similar to that of normal iron metabolism. Triferic is the first and only FDA-approved iron replacement therapy indicated to maintain hemoglobin levels in hemodialysis patients. Its unique and physiologic mechanism of action, excellent safety profile, and potential pharmacoeconomic benefits offer healthcare providers a new alternative in the treatment of anemia in hemodialysis-dependent CKD patients.

PTC Therapeutics, Inc. (NASDAQ: PTCT) recently announced that Translarna™ (ataluren) has been granted marketing approval from the Brazilian National Health Surveillance Agency (ANVISA) under rare diseases procedure, for the treatment of ambulatory children five years and older with Duchenne muscular dystrophy caused by a nonsense mutation. Patients now can have access to a treatment that targets the underlying cause.

"The regulatory approval from the Brazilian authorities will accelerate access to Translarna for the many patients who have been waiting for treatment," stated Eric Pauwels, Senior Vice President and General Manager of the Americas of PTC Therapeutics, Inc. "We are committed to working quickly to make Translarna available to all patients in Brazil who may benefit."

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press releases issued by Guardion Health Sciences, Inc. by the company. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email: editor@financialnewsmedia.com 
+1(561)325-8757

SOURCE FinancialNewsMedia.com